Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

IV Antibiotic Durations for Nontyphoidal Salmonella Bacteremia.

Hess LM, Burdick B, Minard CG, Dutta A.

Hosp Pediatr. 2019 Dec;9(12):993-997. doi: 10.1542/hpeds.2019-0231. Epub 2019 Nov 8.

PMID:
31704707
2.

Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study.

Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L.

J Med Econ. 2019 Oct 23:1-8. doi: 10.1080/13696998.2019.1678479. [Epub ahead of print]

PMID:
31595803
3.

A Case of Sulfhemoglobinemia Secondary to a Urinary Tract Infection.

Campagna G, Espaillat A, Pfeiffer T, Powers JM, McClure M, Hess LM.

J Pediatr Hematol Oncol. 2019 Sep 19. doi: 10.1097/MPH.0000000000001591. [Epub ahead of print]

PMID:
31568176
4.

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.

Hess LM, Brnabic A, Mason O, Lee P, Barker S.

J Cancer. 2019 Jun 9;10(16):3717-3727. doi: 10.7150/jca.32205. eCollection 2019. Review.

5.

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J.

Cancer Control. 2019 Jan-Dec;26(1):1073274819847642. doi: 10.1177/1073274819847642.

6.

Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research.

Hess LM, Zhu YE, Sugihara T, Fang Y, Collins N, Nicol S.

Perspect Health Inf Manag. 2019 Apr 1;16(Spring):1a. eCollection 2019 Spring.

7.

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.

Molife C, Hess LM, Cui ZL, Li XI, Beyrer J, Mahoui M, Oton AB.

Future Oncol. 2019 Sep 1;15(25):2915-2931. doi: 10.2217/fon-2018-0876. Epub 2019 Feb 22.

8.

First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.

Hess LM, DeLozier AM, Natanegara F, Wang X, Soldatenkova V, Brnabic A, Able SL, Brown J.

J Thorac Dis. 2018 Dec;10(12):6677-6694. doi: 10.21037/jtd.2018.11.87.

9.

Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.

Ivanova J, Hess LM, Garcia-Horton V, Graham S, Liu X, Zhu Y, Nicol S.

Patient. 2019 Aug;12(4):393-404. doi: 10.1007/s40271-019-00355-0.

PMID:
30659513
10.

Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA.

Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W.

Int J Colorectal Dis. 2019 Apr;34(4):581-588. doi: 10.1007/s00384-018-03227-5. Epub 2019 Jan 9.

PMID:
30623219
11.

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.

McMullen S, Hess LM, Kim ES, Levy B, Mohamed M, Waterhouse D, Wozniak A, Goring S, Müller K, Muehlenbein C, Aggarwal H, Zhu Y, Oton AB, Ersek JL, Winfree KB.

Patient. 2019 Apr;12(2):223-233. doi: 10.1007/s40271-018-0327-3.

12.

Application and comparison of generalized propensity score matching versus pairwise propensity score matching.

Cui ZL, Hess LM, Goodloe R, Faries D.

J Comp Eff Res. 2018 Sep;7(9):923-934. doi: 10.2217/cer-2018-0030. Epub 2018 Jun 21.

PMID:
29925271
13.

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.

Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D.

Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963. eCollection 2018.

14.

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas.

Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA.

Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x. eCollection 2018.

15.

Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.

Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA.

J Med Econ. 2018 Aug;21(8):755-761. doi: 10.1080/13696998.2018.1467918. Epub 2018 May 11.

PMID:
29673274
16.

Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups.

Sheffield KM, Bowman L, Smith DM, Li L, Hess LM, Montejano LB, Willson TM, Davidoff AJ.

J Comp Eff Res. 2018 Mar;7(3):193-208. doi: 10.2217/cer-2017-0040. Epub 2018 Mar 13.

PMID:
29533694
17.

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.

Paulson AS, Hess LM, Liepa AM, Cui ZL, Aguilar KM, Clark J, Schelman W.

Gastric Cancer. 2018 Sep;21(5):831-844. doi: 10.1007/s10120-018-0796-z. Epub 2018 Feb 3.

PMID:
29397460
18.

Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.

Abrams T, Hess LM, Zhu YE, Schelman W, Liepa AM, Fuchs C.

Gastric Cancer. 2018 Sep;21(5):738-744. doi: 10.1007/s10120-018-0802-5. Epub 2018 Feb 1.

PMID:
29392573
19.

Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.

Hess LM, Kern DM, Carter GC, Winfree K, Wang L, Sontag A, Oton AB.

JMIR Res Protoc. 2017 Oct 11;6(10):e195. doi: 10.2196/resprot.7750.

20.

Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States, European Union, and Japan.

Fenske DC, Price GL, Hess LM, John WJ, Kim ES.

Clin Lung Cancer. 2017 Nov;18(6):607-614. doi: 10.1016/j.cllc.2017.04.011. Epub 2017 Apr 26. Review.

PMID:
28571688
21.

Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040.

Hess LM, Cui ZL, Wu Y, Fang Y, Gaynor PJ, Oton AB.

J Med Econ. 2017 Aug;20(8):850-862. doi: 10.1080/13696998.2017.1333961. Epub 2017 Jun 9.

PMID:
28532187
22.

Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.

Hess LM, Louder A, Winfree K, Zhu YE, Oton AB, Nair R.

J Manag Care Spec Pharm. 2017 Jun;23(6):643-652. doi: 10.18553/jmcp.2017.16389. Epub 2017 Mar 14.

23.

Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USA.

Hess LM, Cui ZL, Wu Y, Li X, Liepa AM, Abraham SM, Schelman W.

J Gastrointest Cancer. 2018 Mar;49(1):25-34. doi: 10.1007/s12029-016-9904-7.

PMID:
27975181
24.

The Patient Experience with Soft Tissue Sarcoma: A Systematic Review of the Literature.

Winnette R, Hess LM, Nicol SJ, Tai DF, Copley-Merriman C.

Patient. 2017 Apr;10(2):153-162. doi: 10.1007/s40271-016-0200-1. Review.

PMID:
27744499
25.

Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy.

Hess LM, Cinfio FN, Wetmore S, Churchill C, Fausel C, Ale-Ali A, Gelwicks S, Bly CA, Perk S, Klein RW.

Hosp Pharm. 2016 Jun;51(6):452-60. doi: 10.1310/hpj5106-452.

26.

Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.

Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C.

Adv Ther. 2015 Dec;32(12):1248-62. doi: 10.1007/s12325-015-0270-9. Epub 2015 Dec 9.

27.

Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, Mannel RS, Puls L, Davidson SA, Method M, Lele S, Havrilesky L, Nelson T, Alberts DS.

Gynecol Oncol. 2015 Dec;139(3):541-5. doi: 10.1016/j.ygyno.2015.10.003. Epub 2015 Oct 9.

28.

Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review.

Carter GC, King DT, Hess LM, Mitchell SA, Taipale KL, Kiiskinen U, Rajan N, Novick D, Liepa AM.

J Med Econ. 2015;18(11):954-66. doi: 10.3111/13696998.2015.1066380. Epub 2015 Sep 11. Review.

PMID:
26212479
29.

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.

Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B.

J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30.

30.

Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.

Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, Winfree KB.

Lung Cancer. 2015 Sep;89(3):294-300. doi: 10.1016/j.lungcan.2015.05.020. Epub 2015 Jun 3.

31.

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data.

Hess LM, Michael D, Mytelka DS, Beyrer J, Liepa AM, Nicol S.

Gastric Cancer. 2016 Apr;19(2):607-615. doi: 10.1007/s10120-015-0486-z. Epub 2015 Mar 20.

32.

Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA.

Mytelka DS, Li L, Stafkey-Mailey D, Liepa AM, Hess LM, Farrelly E, Eaddy M.

Hematology. 2015 Sep;20(8):442-448. doi: 10.1179/1607845414Y.0000000228. Epub 2014 Dec 31.

PMID:
25551431
33.

Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer.

DeLozier AM, Brown J, Natanegara F, Zhao L, Cui ZL, Able SL, Bowman L, Treat J, Hess LM.

Syst Rev. 2014 Sep 16;3:102. doi: 10.1186/2046-4053-3-102.

34.

Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial.

Hess LM, Litwiller A, Byron J, Stutsman J, Kasper K, Learman LA.

Patient. 2015 Apr;8(2):217-27. doi: 10.1007/s40271-014-0078-8.

35.

Perspectives of quality care in cancer treatment: a review of the literature.

Hess LM, Pohl G.

Am Health Drug Benefits. 2013 Jul;6(6):321-9.

36.

Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.

Hess LM, Carter G, Smolen L, Bowman L, von Hohnhorst P, Seagle C.

J Natl Cancer Inst. 2014 Feb;106(2):djt370. doi: 10.1093/jnci/djt370. Epub 2013 Dec 31. No abstract available.

PMID:
24381069
37.

Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.

Hess LM, Brady WE, Havrilesky LJ, Cohn DE, Monk BJ, Wenzel L, Cella D.

Gynecol Oncol. 2013 Feb;128(2):175-80. doi: 10.1016/j.ygyno.2012.10.024. Epub 2012 Oct 30.

38.

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer.

Hess LM, Stehman FB, Method MW, Weathers TD, Gupta P, Schilder JM.

Gynecol Oncol. 2012 Dec;127(3):564-8. doi: 10.1016/j.ygyno.2012.08.029. Epub 2012 Aug 30.

PMID:
22940492
39.

State of the science in ovarian cancer quality of life research: a systematic review.

Hess LM, Stehman FB.

Int J Gynecol Cancer. 2012 Sep;22(7):1273-80. doi: 10.1097/IGC.0b013e318263f02e. Review.

PMID:
22872168
40.

Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Bartels PH, Garcia FA, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Alberts DS.

Gynecol Oncol. 2012 Apr;125(1):129-35. doi: 10.1016/j.ygyno.2011.12.422. Epub 2011 Dec 9.

41.

Cognitive function and quality of life in ovarian cancer.

Correa DD, Hess LM.

Gynecol Oncol. 2012 Mar;124(3):404-9. doi: 10.1016/j.ygyno.2011.11.005. Epub 2011 Nov 15. Review.

PMID:
22094932
42.

Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.

Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y, Alberts DS.

J Support Oncol. 2010 Nov-Dec;8(6):252-8.

PMID:
21265392
43.
44.

Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D.

Cancer. 2010 Nov 15;116(22):5251-60. doi: 10.1002/cncr.25487.

45.

Oncologist preferences for health states associated with the treatment of advanced ovarian cancer.

Hess LM, Malone DC, Skrepnek GH, Reed PG, Armstrong E, Coons SJ.

Appl Health Econ Health Policy. 2010;8(4):217-23. doi: 10.2165/11317510-000000000-00000.

PMID:
20578777
46.

Biomarker targets and novel therapeutics.

Clouser M, Hess LM, Chambers SK.

Cancer Treat Res. 2009;149:85-105. doi: 10.1007/978-0-387-98094-2_4. Review. No abstract available.

PMID:
19763432
47.

Limits of detection of chemopreventive efficacy: karyometry of skin biopsies.

Bartels PH, Yozwiak ML, Bartels HG, Liu Y, Hess LM, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1689-95. doi: 10.1158/1055-9965.EPI-08-0313. Epub 2008 Jun 26.

48.

Factors associated with osteonecrosis of the jaw among bisphosphonate users.

Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS.

Am J Med. 2008 Jun;121(6):475-483.e3. doi: 10.1016/j.amjmed.2008.01.047. Review.

49.

Karyometry of the colonic mucosa.

Alberts DS, Einspahr JG, Krouse RS, Prasad A, Ranger-Moore J, Hamilton P, Ismail A, Lance P, Goldschmid S, Hess LM, Yozwiak M, Bartels HG, Bartels PH.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2704-16.

50.

Chemotherapy-related change in cognitive function: a conceptual model.

Hess LM, Insel KC.

Oncol Nurs Forum. 2007 Sep;34(5):981-94. Review.

PMID:
17878127

Supplemental Content

Support Center